Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site warmth
Clinical narrative: redness at the injection site; warmth at the injection site; tenderness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (tenderness at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     Concurrent medical conditions included Latex allergy. Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL), ARIPIPRAZOLE (ABILIFY), METFORMIN, TAPENTADOL HYDROCHLORIDE (NUCYNTA), PANTOPRAZOLE SODIUM SESQUIHYDRATE (PROTONIX [PANTOPRAZOLE SODIUM SESQUIHYDRATE]), DULOXETINE HYDROCHLORIDE (CYMBALTA), MELOXICAM, VALACICLOVIR, CLONAZEPAM (KLONOPIN), TOPIRAMATE (TOPAMAX), MONTELUKAST SODIUM (SINGULAIR), CEFIXIME (FLEXERIL [CEFIXIME]), FREMANEZUMAB VFRM (AJOVY [FREMANEZUMAB VFRM]) and MELATONIN for an unknown indication.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, the patient experienced VACCINATION SITE PAIN (tenderness at the injection site). On 14-Apr-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (tenderness at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reported additional concomitant medication including  "Unithyroid" and "Phosphorus sulfate".  Reported treatment including Ice pack. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 14-Apr-2021 and was forwarded to Moderna on 14-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (tenderness at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     Concurrent medical conditions included Latex allergy. Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL), ARIPIPRAZOLE (ABILIFY), METFORMIN, TAPENTADOL HYDROCHLORIDE (NUCYNTA), PANTOPRAZOLE SODIUM SESQUIHYDRATE (PROTONIX [PANTOPRAZOLE SODIUM SESQUIHYDRATE]), DULOXETINE HYDROCHLORIDE (CYMBALTA), MELOXICAM, VALACICLOVIR, CLONAZEPAM (KLONOPIN), TOPIRAMATE (TOPAMAX), MONTELUKAST SODIUM (SINGULAIR), CEFIXIME (FLEXERIL [CEFIXIME]), FREMANEZUMAB VFRM (AJOVY [FREMANEZUMAB VFRM]) and MELATONIN for an unknown indication.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, the patient experienced VACCINATION SITE PAIN (tenderness at the injection site). On 14-Apr-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (tenderness at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE WARMTH (warmth at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reported additional concomitant medication including  "Unithyroid" and "Phosphorus sulfate".  Reported treatment including Ice pack.